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Burkholderia cepacia has recently been recognized as an important pathogen in chronic lung disease in
patients with cystic fibrosis (CF). Because of the social, psychological, and medical implications of the isolation
of B. cepacia from CF patients, accurate identification of this organism is essential. We compared the
accuracies of four commercial systems developed for the identification of nonfermenting, gram-negative bacilli
with that of conventional biochemical testing for 150 nonfermenters including 58 isolates of B. cepacia
recovered from respiratory secretions from CF patients. The accuracies of the four systems for identifying all
nonfermenters ranged from 57 to 80%, with the RapID NF Plus system being most accurate. The accuracies of
these systems for identifying B. cepacia ranged from 43 to 86%, with the Remel system being most accurate.
Depending on the commercial system, from two to seven isolates were misidentified as B. cepacia. The relatively
poor performance of the commercial systems requires that identification of certain nonfermenters be con-
firmed by conventional biochemical testing. These organisms include B. cepacia, Burkholderia sp. other than B.
cepacia, and infrequently encountered environmental species (Pseudomonas and Flavobacterium species). In
addition, conventional biochemical testing should be done if a commercial system fails to assign an identifi-
cation to an organism. Confirmatory testing should preferably be performed by a reference laboratory with
experience in working with organisms isolated from CF patients.
Chronic lung infection caused by a limited variety of micro-
organisms is responsible for greater than 90% of the prema-
ture deaths seen in individuals with cystic fibrosis (CF) (7). The
most important cause of chronic lung infection in these pa-
tients is an unusual phenotype of Pseudomonas aeruginosa
referred to as mucoid. These organisms are easily recognized
by their typical colonial morphology (7). During the past de-
cade, another nonfermenter, Burkholderia cepacia, has been
recognized as an important agent of pulmonary disease in
these patients (7, 12, 20). Two factors are important when
considering this organism. First, approximately 20% of pa-
tients who became infected with this organism will have a rapid
decline in their pulmonary function, some will become bacte-
remic, and death will occur in 1 to 6 months. Patients fitting
this clinical course are said to have the ‘‘cepacia syndrome’’ (7,
20). Serious infection with this organism has not been reported
in patients with other types of chronic pulmonary diseases.
Second, there is accumulating evidence that at least some
clones of B. cepacia can be transmitted from person to person
(10, 16, 19). The practice of cohorting B. cepacia-infected pa-
tients from all other CF patients has been done to prevent the
spread of this organism (21). This practice has clear social and
psychological impacts on the infected patients. In addition, B.
cepacia-infected patients are not considered candidates for
lung transplants at most centers, although this exclusion is
controversial (6, 18, 19).
Because of the medical, social, and psychological impacts of
the recovery of B. cepacia from a CF patient, accurate iden-
tification of this organism is critical. Many laboratories use
commercial identification systems to identify nonfermenting
gram-negative bacilli, even though there are no published eval-
uations of the accuracies of these systems in identifying this
group of organisms recovered specifically from CF patients.
Often, these evaluations are not undertaken because of prob-
lems encountered with CF patient-derived nonfermenting iso-
lates. These include phenotypic variation and slower growth
rates because of the significant antimicrobial pressure that
these organisms face in the lungs of CF patients.
In the study described here, we compared the accuracies of
four commercially available identification systems with that of
conventional biochemical testing to identify nonfermenting
gram-negative bacilli recovered from respiratory secretions
from CF patients.
MATERIALS AND METHODS
Test organisms. A total of 150 clinical isolates of nonfermenting gram-nega-
tive bacilli recovered from the respiratory tracts of CF patients were tested in the
study. One hundred nine of these strains were collected and tested prospectively
beginning in January 1994 and continuing to January 1995. The remaining 41
strains, including 37 B. cepacia isolates, were clinical isolates obtained from
frozen strain collections of the Microbiology Laboratories of the University of
North Carolina Hospitals and Columbia-Presbyterian Medical Center, New
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York, N.Y. Multiple isolates of the same species from an individual patient were
not tested. The P. aeruginosa strains included in the study were only those
isolates which did not demonstrate characteristic colonial morphology on pri-
mary isolation plates; i.e., they were not mucoid and/or did not produce charac-
teristic pigment and therefore were not readily recognized as P. aeruginosa.
Isolate preparation. Fresh clinical isolates were subcultured onto Trypticase
soy agar with 5% sheep blood (SBA) and were incubated at 358C in an ambient
atmosphere for 24 h. Most B. cepacia strains required 48 h for sufficient growth.
Frozen stocks of clinical isolates were stored in skim milk at 2708C and were
subcultured twice onto SBA before inoculation of the test systems. Prior to
inoculation, the SBA plates were inspected for purity, and oxidase testing of each
organism was performed with 1% tetramethyl p-phenylenediamine dihydrochlo-
ride. This oxidase result was used for all of the identification systems except the
RapID NF Plus system, which provided an oxidase reagent.
Conventional biochemical testing. The following tests and media were pre-
pared in house: triple sugar iron (TSI); citrate; urea; lysine decarboxylase; orni-
thine decarboxylase; arginine dihydrolase; oxidation-fermentation (OF) sugars
(glucose, xylose, lactose, mannitol, sucrose, maltose, fructose, galactose, man-
nose) with bromthymol blue as a pH indicator; o-nitrophenyl-b-D-galactoside
(ONPG); nitrate reduction and gas; gelatin; esculin; egg yolk agar for lecithinase
activity; litmus milk; cetrimide; flo; tech; growth at 428C; hemolysis; motility; and
growth on MacConkey, PC, and OFPBL agars. PC and OFPBL agars are selec-
tive media used in the isolation of B. cepacia from clinical specimens (9, 24).
Medium components and reagents were purchased from the following manufac-
turers: Difco, Detroit, Mich.; Becton-Dickinson MicroSystems, Cockeysville,
Md.; or Sigma Chemical, St. Louis, Mo.
All biochemical tests and media were incubated at 358C in an ambient atmo-
sphere and were examined at 2, 3, 5, and 7 days, with the exceptions of TSI slants,
which were examined at 24 h; tests with ONPG, which was examined at 48 h; and
tests with nitrate, Pseudomonas cepacia, and OFPBL (oxidative fermentation
base-polymyxin B-bacitracin-lactose) media, which were examined at 72 hours.
Organisms routinely used for quality control of the media included Enterobacter
aerogenes, Oligella urealyticum, Flavobacterium meningosepticum, Acinetobacter
calcoaceticus var. anitratus, and Aeromonas hydrophila. Flagellar staining (Carr
Scarborough Microbiologicals, Decatur, Ga.) was performed when necessary to
supplement conventional biochemical testing. Organism identification was based
on a comparison of the biochemical reactions obtained at the completion of each
test with tables found in the Pseudomonas and Burkholderia chapter in the 6th
edition of the Manual of Clinical Microbiology (8).
Commercial identification systems. The commercial systems used in the
present study included RapID NF Plus (Innovative Diagnostic Systems, Nor-
cross, Ga.), API Rapid NFT (bioMérieux-Vitek, Hazelwood, Mo.), Vitek Auto/
Microbic System GNI (bioMérieux-Vitek) and Uni-N/F Tek and N/F Screen
(Remel, Lenexa, Kans.). Preparation of organism suspensions, inoculation, in-
cubation times and temperatures, interpretation of reactions, and quality control
were according to the manufacturers’ recommendations for each system. Tech-
nologists performing organism identifications did not know the identity of the
organism prior to inoculation or the interpretation of the test results. Ten
isolates identified by conventional biochemical testing as B. cepacia were selected
at random and were tested three different times to determine the reproducibil-
ities of the commercial systems for identifying B. cepacia.
Data analysis. The identifications obtained with the four commercial systems
were compared with the identifications obtained by the conventional biochemical
reference method. The identifications with the commercial systems were consid-
ered correct if they agreed with the reference method to the species level without
the need for supplemental testing. RapID NF Plus identifications were accepted
as correct if the biocode designation was implicit, satisfactory, or adequate,
corresponding to a likelihood of.95%. API Rapid NFT biocode designations of
excellent, very good, or good were accepted as correct, representing a likelihood
of $90%. Correct identification with the Vitek system required a likelihood of
$90%. Biocode designations of excellent or good with the Remel system were
accepted as correct, representing a likelihood of $90%.
The identifications obtained with the commercial systems were considered to
be incomplete if the identification obtained by the reference method was listed
among two or more choices. Such identifications were referred to as probability
overlaps by the RapID NF Plus system, a good identification to the genus level
or a low level of discrimination by the API Rapid NFT system, good confidence
or marginal separation by the Vitek system, and unacceptable by the Remel
system. Any organism that gave a discrepant identification with one or more of
the commercial systems was referred for confirmatory identification to the Spe-
cial Bacteriology Laboratory of the North Carolina State Laboratory of Public
Health. A small percentage of strains were referred to the Centers for Disease
Control and Prevention, Atlanta, Ga., for confirmatory identification. Both ref-
erence laboratories used conventional biochemical testing for organism identi-
fication. Comparison of system performances was assessed by the x2 test. For
overall performance comparisons with the API/Rapid NFT, Vitek, and Remel
systems, the data for Burkholderia gladioli were not included since this organism
was not in the databases for these systems.
RESULTS
The results of the comparisons of the identifications ob-
tained with the four commercial systems with those obtained
with conventional biochemicals are given in Tables 1 to 4.
There was no difference in the performance of the systems
when identifications of frozen isolates were compared with
those of prospectively collected isolates (data not shown).
Overall, the RapID NF Plus system was the most accurate
commercial system for identifying nonfermenters (Table 1).
However, the RapID NF Plus system accurately identified only
47 of 58 (81%) B. cepacia isolates. Eight isolates were identi-
fied as belonging to the Alcaligenes faecalis-Alcaligenes odorans
group (Table 2). Biocodes for all eight isolates were similar,
and all eight isolates were negative for g-glutamyl-b-naphthyl-
amide (GGT), a key test for the identification of B. cepacia by
this system. Six of eight isolates would have been correctly
identified if the GGT result had been positive. In addition,
three isolates required supplemental testing to allow B. cepacia
to be accurately distinguished from other species of nonfer-
menters (Table 4). Seven of the 150 isolates were misidentified
as B. cepacia (Table 3). Five of those seven misidentified iso-
lates were B. gladioli (two isolates) and Burkholderia pickettii
(three isolates). Particularly problematic for this system was
the identification of other species of Burkholderia other than B.
cepacia, some of which were identified as B. cepacia (Table 3).
Of the 10 isolates selected for reproducibility studies by the
RapID NF Plus system, 7 were initially identified correctly. Six
isolates were correctly identified on both retests, one isolate
was identified correctly once and incorrectly once on retesting,
and two isolates were misidentified all three times that they
were retested. One isolate identified incorrectly twice as A.
faecalis was correctly identified as B. cepacia on the third at-
tempt.
The API Rapid NFT system accurately identified 25 of 58
(43%) of the B. cepacia isolates (Table 1). Of the five incorrect
identifications, two were identified as B. pickettii and three
were identified as fluorescent pseudomonads (Table 2). In
addition, seven isolates (five B. gladioli and two B. pickettii
isolates) were misidentified as B. cepacia (Table 3). There were
18 incomplete identifications of B. cepacia with the API Rapid
NFT system. The majority of these were due to the inability of
this system to differentiate B. cepacia from Pseudomonas au-
reofaciens. An additional xylose oxidation test would allow
these two organisms to be separated and would improve the
accuracy of the API Rapid NFT system for identifying B.
cepacia to 74%. Ten biocodes were not found in either the
code book or the company’s phone access computer database.
B. gladioli was not in the API Rapid NFT system’s database,
but this organism was frequently identified as some other spe-
cies, particularly B. cepacia (five of nine isolates). Only one
isolate of B. gladioli was not assigned an identification by the
system.
Reproducibility studies of the API Rapid NFT system
showed that six B. cepacia isolates were correctly identified
initially. Only one of those six isolates was correctly identified
on two retests. Four isolates either were not identified (two
isolates) or were identified as non-Burkholderia species (two
isolates). Two isolates which were misidentified originally were
identified as B. cepacia on both retests. No identification was
obtained for two organisms in all three trials of the NFT
system.
The API Rapid NFT system performed inadequately for the
identification of Alcaligenes xylosoxidans and P. aeruginosa (Ta-
ble 1). The problems encountered in the identification of A.
xylosoxidans were generally due to strains with negative glucose
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assimilation test results. These strains also tested negative by
conventional OF glucose oxidation tests. The poor perfor-
mance of the API Rapid NFT system in identifying P. aerugi-
nosa was not due to the failure of any characteristic reac-
tion(s). It should be noted that three strains identified by
conventional biochemical testing as atypical P. aeruginosa were
incorrectly identified by the API Rapid NFT system.
Only 50% of the B. cepacia strains were correctly identified
by using the Vitek system (Table 1). Seven B. cepacia isolates
were incorrectly identified as B. pickettii (Table 2). Ten B.
cepacia isolates were not identified by the Vitek system. Only
two isolates, a B. gladioli isolate and a B. pickettii isolate, were
misidentified as B. cepacia. Twelve B. cepacia isolates required
supplemental testing to differentiate them from B. pickettii.
The addition of lysine decarboxylase, ONPG, and growth on
cetrimide tests improved the accuracy of the Vitek system to
71% for B. cepacia. The majority of strains requiring supple-
mental testing exhibited negative lysine decarboxylase test re-
sults with the Vitek system. When the result of this test was
keyed into the Vitek system as positive, the likelihood of iden-
tification as B. cepacia became .99% for 10 of the 12 isolates.
The Vitek system correctly identified only 13 of 24 A. xylosoxi-
dans strains. This low level of performance was due mainly to
negative OF glucose and xylose test results. The corresponding
conventional OF glucose and OF xylose test results were either
negative or required 5 to 7 days for the development of a
positive reaction.
Five of 10 B. cepacia isolates were correctly identified ini-
TABLE 1. Identification of glucose-nonfermenting bacilli by commercial systems
Organism No. of isolates System
No. (%) of isolates with the following identification:
Correcta Incompleteb Incorrect Unidentified
B. cepacia 58 RapID NF Plus 47 (81) 3 8 0
API Rapid NFT 25 (43) 18 5 10
Vitek 29 (50) 12 7 10
Remel 50 (86) 5 0 3
S. maltophilia 30 RapID NF Plus 30 (100) 0 0 0
API Rapid NFT 26 (87) 1 1 2
Vitek 28 (93) 0 1 1
Remel 30 (100) 0 0 0
A. xylosoxidans subsp. xylos 24 RapID NF Plus 21 (88) 0 3 0
API Rapid NFT 17 (71) 2 1 4
Vitek 13 (54) 4 5 2
Remel 5 (21) 13 6 0
P. aeruginosa 14 RapID NF Plus 13 (93) 1 0 0
API Rapid NFT 8 (57) 1 2 3
Vitek 9 (64) 2 2 1
Remel 7 (50) 2 5 0
B. gladioli 9 RapID NF Plus 2 0 7 0
API Rapid NFTc 0 0 8 1
Vitekc 0 0 6 3
Remelc 0 0 8 1
B. pickettii (biovar 1) 3 RapID NF Plus 1 0 2 0
API Rapid NFT 0 1 1 1
Vitek 0 1 1 1
Remel 1 0 2 0
B. pickettii (biovar 3) 3 RapID NF Plus 1 0 2 0
API Rapid NFT 0 0 3 0
Vitek 1 1 1 0
Remel 3 0 0 0
Otherd 9 RapID NF Plus 5 1 3 0
API Rapid NFT 4 2 2 1
Vitek 4 2 3 0
Remel 5 0 4 0
Total 150 RapID NF Plus 120 (80) 5 25 0
141 API Rapid NFT 80 (57) 25 15 21
141 Vitek 84 (60) 22 20 15
141 Remel 101 (72) 20 17 3
a Identification to the species level without supplemental testing.
b Low level of discrimination; the correct identification was listed among two or more choices.
c B. gladioli not in the databases of the API Rapid NFT, Vitek, and Remel systems.
d A. calcoaceticus var. anitratus (n 5 2), A. calcoaceticus var. lwoffii (n 5 1), A. xylosoxidans denitrificans (n 5 2), Flavobacterium oryzihabitans (n 5 1), Pseudomonas
diminuta (n 5 1) (not in Vitek database), and Pseudomonas putida (n 5 2) (Pseudomonas putida/Pseudomonas fluorescens considered correct for Rapid NF Plus, Vitek,
and Remel systems).
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tially in reproducibility studies with the Vitek system. Three of
the five isolates were correctly identified on both retests; the
other two isolates were correctly identified on one retest, and
no identification was obtained for the other isolate. One isolate
which gave no identification on initial testing was correctly
identified on two retests. Four isolates were misidentified or
gave no identification all three times that they were tested.
The Remel system was the most accurate commercial system
for the identification of B. cepacia. This system correctly iden-
tified 50 of 58 (86%) B. cepacia strains (Table 1). No B. cepacia
isolate was incorrectly identified. Four isolates, two B. gladioli
isolates and two B. pickettii isolates, were misidentified as B.
cepacia (Table 3). In addition, five B. cepacia isolates required
further testing to distinguish them from Flavobacterium spp.
(Table 4).
Eight of 10 B. cepacia isolates were identified correctly on
initial testing in the reproducibility studies with the Remel
system. Four isolates were identified correctly on both retests;
four isolates were incorrectly identified as other organisms on
both retests. Two isolates which were given no identification
initially were identified correctly as B. cepacia on both retests.
The major weakness of the Remel system was the difficulty
encountered in identifying both A. xylosoxidans and nonpig-
mented P. aeruginosa isolates. Fifteen of the A. xylosoxidans
isolates exhibited a positive glucose reaction at 24 h, which
resulted in the inability of the system to distinguish this organ-
ism from B. pickettii. A negative glucose reaction would have
generated a correct identification of A. xylosoxidans. This sys-
tem also failed to identify 50% of the P. aeruginosa isolates.
This failure was due in part to the fact that several strains were
negative for pigment production, a key characteristic in the
Remel identification scheme for this organism. In addition,
three strains giving either incorrect or incomplete results were
identified as atypical P. aeruginosa isolates by conventional
biochemical tests.
DISCUSSION
At least in some clinical situations, and some might argue in
many clinical situations, the accurate identification of micro-
organisms to the species level is of limited importance in the
clinical care of a patient. It can be argued that accurate anti-
microbial susceptibility test results for organisms which are not
reliably susceptible to specific groups of antimicrobial agents
have greater clinical utility. Species-level identification be-
comes more important when identifying infection outbreaks or
attempting to understand the pathologic potential of infre-
quently or newly encountered organisms.
Accurate isolation and identification of B. cepacia from the
respiratory tracts of patients with CF is critical for the care of
not only the individual patient but also the community of
individuals with CF. This is due to the transmissibility of at
least some B. cepacia clones in this population (10, 16) and the
significant mortality associated with infection with this organ-
ism (7, 20). Cohorting CF patients infected with B. cepacia has
been shown to be effective in reducing the transmission of this
organism (21). Cohorting may result in the infected individual
being separated from close friends. Cases in which siblings with
CF in which one child is infected and the others are not or
cases in which individuals with CF who are involved in amo-
rous relationships in which one member is infected and the
other is not are two of the more difficult situations facing these
patients’ caregivers. This is especially true because B. cepacia
transmission has occurred in the second situation cited and has
resulted in the death of the previously uninfected partner (10).
Published evaluations exist for each of the four commercial
systems evaluated in the present study (1, 2, 4, 11, 14, 15, 17,
22, 23). However, only one of those studies, the one by Kitch
et al. (11), specifically states if any of their study isolates were
recovered from CF patients. Kitch et al. (11) evaluated the NF
RapID Plus system and found that 88% (n 5 27) of B. cepacia
isolates were identified accurately, which was consistent with
our finding of 81% accuracy. In their study, 85% of the B.
cepacia isolates were from CF patients. All eight isolates of B.
cepacia incorrectly identified in our study were identified as
belonging to the A. faecalis-A. odorans group, an organism
group which was not found in our CF population. An identi-
fication of a member of the A. faecalis-A. odorans group with
the NF RapID Plus system should be confirmed by an alter-
native method to ensure that a B. cepacia isolate is not being
incorrectly identified.
In the study by Kitch et al. (11), too few isolates of other
Burkholderia spp. (n 5 2) were studied to determine the fre-
quency with which those organisms were misidentified as B.
cepacia. In the current study, 5 of 15 B. gladioli or B. pickettii
isolates were misidentified as B. cepacia by the NF RapID Plus
system. Both B. gladioli and B. pickettii appear to be commen-
sal organisms in CF patients (5, 8).
Two groups have previously evaluated earlier versions of the
API Rapid NFT system (1, 23). They found the system to be
very accurate in identifying B. cepacia. A total of only 28







RapID NF Plus 8 Alcaligenes faecalis-Alcaligenes odorans (8)




Vitek 7 Burkholderia pickettii (biovar 3) (4)
Burkholderia pickettii (biovar 1) (2)
Burkholderia pickettii (biovar 3)/Flavobacterium
oryzihabitans (1)
Remel 0
TABLE 3. Organisms misidentified as B. cepacia
System Total no.of isolates
Organism identification
(no. of isolates)
RapID NF Plus 7 Burkholderia gladioli (2)
Burkholderia pickettii (biovar 3) (2)




API Rapid NFT 7 Burkholderia gladioli (5)
Burkholderia pickettii (biovar 3) (2)
Vitek 2 Burkholderia gladioli (1)
Burkholderia pickettii (biovar 3) (1)
Remel 4 Burkholderia gladioli (2)
Burkholderia pickettii (biovar 1) (2)
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isolates of B. cepacia were studied and were correctly identified
by the two groups. In the two studies, the system correctly
identified all 20 B. pickettii isolates tested. Two isolates of
Burkholderia pseudomallei were identified as B. cepacia (23).
Since B. pseudomallei is not encountered in North America or
northern Europe, the area where most CF patients reside,
these misidentifications are not likely to occur with isolates
from CF patients. Their data are in direct contrast to our
findings. We found that less then half of the B. cepacia isolates
tested were correctly identified as B. cepacia. The API Rapid
NFT system often did not distinguish B. cepacia from Pseudo-
monas aureofaciens. P. aureofaciens is an environmental organ-
ism which has not been isolated from clinical specimens (13).
Therefore, the inability of this system to distinguish between B.
cepacia and P. aureofaciens isolates is of little practical clinical
importance. If those 13 isolates were considered as being cor-
rectly identified, the accuracy of the API Rapid NFT system
would improve to 66%. Seven of 15 other Burkholderia isolates
were identified as B. cepacia by the API Rapid NFT system.
One of the problems with this system was that B. gladioli was
not in the API Rapid NFT system’s database. Instead of not
giving an identification for this organism, the system assigned
an incorrect identification to eight of nine B. gladioli isolates,
including five as B. cepacia.
The Vitek card has been evaluated in several laboratories
(14, 15, 17, 22). However, only two studies have evaluated the
system with multiple isolates of B. cepacia and related organ-
isms. In an early evaluation (17), 29 of 31 isolates of B. cepacia
were correctly identified. However, only nine of the isolates
were from clinical sources. Other organisms including P.
aeruginosa, Pseudomonas putida, and Stenotrophomonas mal-
tophilia were misidentified as B. cepacia. In the second evalu-
ation (15), 27 of 32 B. cepacia isolates were correctly identified.
The problem of misidentification appears to have been ad-
dressed in the database since no isolates were misidentified in
the study (15). In our study, 29 of 58 B. cepacia strains were
accurately identified by the Vitek system. A major problem
with the Vitek system was its inability to distinguish B. cepacia
from B. pickettii. Seven isolates of B. cepacia were identified as
B. pickettii and 12 isolates were incompletely identified. Inter-
estingly, only 2 of 15 other Burkholderia spp. were misidentified
as B. cepacia. This verifies previous findings that this system
only infrequently misidentifies these organisms as B. cepacia. It
would be prudent for users of the Vitek system to confirm the
identities of all isolates identified as B. pickettii by alternate
means to ensure that these isolates are not B. cepacia.
Of the commercial nonfermenting gram-negative bacillus
identification systems evaluated in the present study, the Re-
mel system has been used for the longest period of time.
Results of early studies showed that the Remel system accu-
rately identified all B. cepacia isolates tested, although only a
small number of isolates (n 5 20) were studied (2, 4). In our
study, the Remel system was the most accurate system for
identifying B. cepacia. It did not incorrectly identify any of the
58 isolates. Five B. cepacia isolates could not be distinguished
from two different Flavobacterium spp. As was the case with all
of the other systems tested, distinguishing the closely related
Burkholderia spp. from B. cepacia was problematic.
The answer to the question of what approach should be used
to identify members of the Burkholderia genus is not clear.
Commonly used commercial identification systems are flawed
for the identification of B. cepacia, although the RapID NF
Plus and Remel systems were accurate (P , 0.001) and the
results were relatively reproducible when compared with those
of the API Rapid NFT and Vitek systems prior to supplemen-
tal testing. Because the RapID NF Plus system is enzyme
based, its ability to identify weakly oxidizing B. cepacia isolates
and atypical P. aeruginosa isolates may be enhanced compared
with those of the other commercial systems. It is clear that
difficulty in differentiating members of the Burkholderia genus
was encountered with all systems. Conventional biochemical
batteries incubated for 7 days appear to be the most accurate
method for identifying members of the Burkholderia genus.
Even this approach to the determination of species has not
been validated by using isolates whose species were deter-
mined either by DNA hybridization or by sequence analysis,
both of which are highly specific but not widely available tech-
niques (3). Until easily applied genetic techniques which can
discriminate between species of Burkholderia are available,
these organisms will continue to be difficult to distinguish. The
initial isolate from a CF patient identified as a Burkholderia sp.
with a commercial identification system should be sent to a
reference laboratory which uses conventional biochemical test-
ing to confirm the identity of that organism. Laboratories
should also be cognizant of the fact that they may experience
difficulty in distinguishing B. cepacia from other organisms
when using currently available commercial ID systems. If an
identification system lists organisms which are primarily envi-
TABLE 4. Supplemental tests required for the identification of B. cepacia





RapID NF Plus 3 Chromobacterium violaceum versus Burkholderia cepacia (1) Pigmentation
Pseudomonas alcaligenes versus Moraxella liquefaciens versus Moraxella osloensis
versus Burkholderia cepacia (1)
Motility, glu, xyl
Burkholderia cepacia versus Acinetobacter sp. (1) Motility, mann
API Rapid NFT 18 Burkholderia cepacia versus Pseudomonas aureofaciens (13) xyl
Burkholderia cepacia versus Pseudomonas aureofaciens versus Pseudomonas
fluorescens (4)
xyl, lys, 428C
Burkholderia cepacia versus Pseudomonas aureofaciens versus Pseudomonas
fluorescens versus Pseudomonas aeruginosa (1)
xyl, lys, 428C, lac
Vitek 12 Burkholderia cepacia versus Burkholderia pickettii (biovar 3) (11) lys, ONPG, cet
Burkholderia cepacia versus Burkholderia pickettii (biovar 1) (1) lys, ONPG, cet
Remel 5 Burkholderia cepacia versus Flavobacterium oryzihabitans (3) lys
Burkholderia cepacia versus Flavobacterium indologenes (2) motility, lac, mann
a glu, OF glucose; xyl, OF xylose; mann, OF mannitol; lys, lysine decarboxylase; lac, OF lactose; cet, cetrimide.
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ronmental organisms (P. aureofaciens) for an isolate recovered
from a CF patient, the laboratory should be highly suspicious
that the isolate may be B. cepacia and that such isolates should
be sent for conventional testing as well. Finally, isolates which
do not appear in the database of the commercial systems
should also be identified by conventional biochemical tests.
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